# Treating Severe Childhood Epilepsy with Fenfluramine

> This patent describes a specific way to treat Lennox-Gastaut Syndrome, a severe form of childhood epilepsy, by giving patients a controlled dose of the drug fenfluramine.

- **Patent:** US 12734137
- **Original title:** Methods of treating Lennox-Gastaut Syndrome using fenfluramine
- **Granted:** 2026
- **Status:** Active
- **Times cited:** 0
- **Field:** pharmaceutical, biotech

## What it does

This patent describes a method for treating or preventing symptoms of Lennox-Gastaut Syndrome (LGS), a severe type of epilepsy, in a patient. The method involves giving the patient an effective dose of fenfluramine or its pharmaceutically acceptable salt. Specifically, the patent mentions a preferred dosage range for LGS patients of less than about 2.0 to about 0.01 milligrams per kilogram of body weight per day. For example, a child previously diagnosed with LGS would receive fenfluramine within this precise daily dosage range to help manage their seizures.

## What it does NOT cover

- Does not cover using fenfluramine to treat other types of epilepsy or medical conditions not identified as Lennox-Gastaut Syndrome.
- Does not cover treating Lennox-Gastaut Syndrome with other medications that are not fenfluramine or its pharmaceutically acceptable salts.
- Does not cover administering fenfluramine at dosages outside the specified range of less than about 2.0 to about 0.01 mg/kg/day for LGS.
- Does not cover methods of preventing LGS symptoms that do not involve administering fenfluramine.

## The clever bit

The novelty lies in identifying fenfluramine, a drug with a complex history, as an effective treatment for Lennox-Gastaut Syndrome at a specific, carefully defined low dosage. This precise application to a rare, difficult-to-treat epilepsy was not widely recognized before.

## Real-world examples

1. Fintepla (fenfluramine) oral solution for Lennox-Gastaut Syndrome
2. Treatments for severe childhood epilepsies

## Why it matters

Lennox-Gastaut Syndrome is a rare and severe form of childhood epilepsy that is often resistant to many standard treatments, leading to frequent seizures and developmental delays. Finding effective treatments for LGS is crucial for improving the quality of life for patients and their families. This patent focuses on a specific drug, fenfluramine, which has shown efficacy in managing this challenging condition.

## Frequently asked questions

### What does Treating Severe Childhood Epilepsy with Fenfluramine cover?

This patent describes a specific way to treat Lennox-Gastaut Syndrome, a severe form of childhood epilepsy, by giving patients a controlled dose of the drug fenfluramine.

### When does this patent expire?

This patent is expected to expire on September 15, 2046, when the invention enters the public domain.

### What problem does this patent solve?

Lennox-Gastaut Syndrome is a rare and severe form of childhood epilepsy that is often resistant to many standard treatments, leading to frequent seizures and developmental delays. Finding effective treatments for LGS is crucial for improving the quality of life for patients and their families. This patent focuses on a specific drug, fenfluramine, which has shown efficacy in managing this challenging condition.

### What does this patent NOT cover?

Does not cover using fenfluramine to treat other types of epilepsy or medical conditions not identified as Lennox-Gastaut Syndrome.

**Full plain-English explainer:** https://patentbrief.org/patent/us/12734137/methods-of-treating-lennox-gastaut-syndrome-using-fenfluramine

**Original patent:** https://patents.google.com/patent/US12734137

---

_Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._